Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional Phase 3 studies of azetukalner continue to enroll in ep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results